10-Q: Cavitation Technologies Reports Net Income for Nine Months Ended March 31, 2025, Despite Revenue Decline

Sentiment:

Quarterly Report


Cavitation Technologies reports a net income of $122,000 for the nine months ended March 31, 2025, despite a significant decrease in revenue due to a patent assignment with Desmet.

Capital raiseThe Company may also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital.There is no assurance that such financing will be available in the future or obtained in sufficient amounts necessary to meet the Company's needs.
Worse than expectedRevenue decreased significantly for the three and nine months ended March 31, 2025, compared to the same periods in 2024.

Summary

  • Cavitation Technologies, Inc. reported its financial results for the quarter and nine months ended March 31, 2025.
  • The company had a net loss of $230,000 for the three months ended March 31, 2025, compared to a net income of $331,000 for the same period in 2024.
  • Revenue for the three months ended March 31, 2025, was $122,000, a decrease of 76.5% compared to $519,000 in 2024.
  • For the nine months ended March 31, 2025, the company reported a net income of $122,000, compared to a net income of $64,000 for the same period in 2024.
  • Revenue for the nine months ended March 31, 2025, was $198,000, a decrease of 72.2% compared to $711,000 in 2024.
  • The company assigned certain patents to Desmet in October 2024 for $880,000, which contributed to the net income for the nine-month period.
  • The company's management plans to increase revenues by focusing on water treatment, remediation, and alcoholic beverage enhancement using its Reserved Grant Back License.
  • The company believes it has enough cash to sustain operations through June 30, 2025.
  • The company may also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company reported a net income for the nine-month period, it was primarily due to a one-time gain from a patent assignment. Revenue decreased significantly, and the company's auditor has raised concerns about its ability to continue as a going concern.

Positives

  • The company reported a net income of $122,000 for the nine months ended March 31, 2025.
  • The company received $880,000 from the patent assignment to Desmet.
  • Cash and cash equivalents increased to $432,000 as of March 31, 2025.
  • The company extinguished $462,000 of accrued payroll and payroll taxes through the issuance of common stock and warrants.
  • The company is actively pursuing new revenue streams in water treatment and alcoholic beverage enhancement.

Negatives

  • Revenue decreased significantly, by 72.2%, for the nine months ended March 31, 2025.
  • The company incurred a loss from operations of $753,000 during the nine months ended March 31, 2025.
  • The company's independent auditor has raised substantial doubt about the company's ability to continue as a going concern.
  • The company's disclosure controls and procedures were not effective as of March 31, 2025.

Risks

  • The company's ability to continue as a going concern is dependent on its ability to increase revenues and/or obtain additional financing.
  • The company's reliance on new ventures in water treatment and alcoholic beverage enhancement carries inherent risks.
  • The company's future revenues from Desmet are expected to be significantly reduced.
  • The company's disclosure controls and procedures were not effective as of March 31, 2025.
  • Global inflation and geopolitical conflicts could negatively impact the company's operating costs and supply chain.

Future Outlook

Management plans to increase revenues by focusing on water treatment, remediation, and alcoholic beverage enhancement using its Reserved Grant Back License; the company anticipates sales will be generated in the first half of fiscal 2026 from water treatment in the Permian Basin; the earliest sales and revenue for Barmuze are anticipated in the second half of 2026; testing of the Hydro-Plasma technology is currently underway, and if successful, sales and revenue are anticipated in the first half of fiscal 2026.

Management Comments

  • Management plans to increase revenues by focusing on water treatment, remediation, and alcoholic beverage enhancement using its Reserved Grant Back License.
  • The Company believes it has enough cash to sustain operations through June 30, 2025.

Industry Context

The company is operating in the water treatment and alcoholic beverage enhancement industries, which are experiencing growth due to increasing demand for sustainable solutions and innovative products; the global cold plasma market is projected to grow from $1.5 billion in 2021 to $3.1 billion by 2027, fueled by increasing demand for sustainable water solutions.

Comparison to Industry Standards

  • It is difficult to compare Cavitation Technologies directly to industry standards due to its unique technology and business model.
  • However, companies in the water treatment industry, such as Ecolab and Veolia, typically have higher revenue and profitability due to their larger scale and established market presence.
  • Similarly, companies in the alcoholic beverage industry, such as Diageo and Anheuser-Busch InBev, have significantly larger revenue and market capitalization compared to Alchemy Beverages, Inc.

Related Party Transactions

  • The company settled accrued payroll and payroll taxes with a former and current officer by issuing 4,666,600 shares of common stock and warrants to purchase 5,000,000 shares.

Stakeholder Impact

  • Shareholders: The company's financial performance and future prospects may impact shareholder value.
  • Employees: The company's ability to continue as a going concern may impact employee job security.
  • Customers: The company's focus on new ventures may impact the availability and quality of its products and services.
  • Creditors: The company's ability to repay its debts is dependent on its ability to generate revenue and/or obtain additional financing.

Next Steps

  • The company plans to focus on water treatment and alcoholic beverage enhancement to generate future revenues.
  • The company will continue testing its Hydro-Plasma technology.
  • The company may attempt to raise additional debt and/or equity financing.

Key Dates

DateDescription
2007-01-01Cavitation Technologies, Inc. originally incorporated as Bio Energy, Inc.
2008-07-01Subsidiary entered into Patent Assignment Agreements with President and former CEO.
2010-05-13Patent Assignment Agreements assigned to Cavitation Technologies.
2018-06-01Company entered into an agreement to license its patented alcoholic beverage technology to Alchemy Beverages, Inc.
2020-07-01Company received a $150,000 loan from the SBA under its Economic Injury Disaster Loan (EIDL) assistance program.
2021-10-01Company signed a three-year global Research and Development, Marketing and Technology License Agreement (TLA) with Desmet Ballestra (Desmet) for the sale and licensing of the Company's nano reactors.
2024-02-01Desmet and the Company terminated the October 2021 TLA agreement and entered into a new three-year Technology License Agreement (February 2024 TLA).
2024-10-08Patent Assignment and License Back Agreement with Desmet.
2024-10-09Company entered into a patent assignment and license back agreement with Desmet.
2025-02-01Company settled with the former officer and current officer to extinguish the accrued payroll and payroll related taxes amounting to $462,000.
2025-03-31End of the quarterly period.
2025-05-15Date of report filing; issuer had 288,956,340 shares of common stock outstanding.
2025-06-30Company believes it has enough cash to sustain operations through this date.

Keywords

Cavitation Technologies, financial results, patent assignment, Desmet, Nano Reactor, water treatment, alcoholic beverages, revenue, net income, going concern

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.